Pharvaris (PHVS) EBIT Growth (3y) (2023 - 2026)

Pharvaris (PHVS) EBIT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 8.36%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 89.72%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 44.54%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -26.00%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -18.82%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 44.34%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 81.27%
10 Pharvaris 2.29 Bn 1.92 Bn - -32.24%

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.24%
Mar 31, 2026 98.68%
Dec 31, 2025 -37.85%
Sep 30, 2025 98.73%
Jun 30, 2025 -69.40%
Mar 31, 2025 -1,268,207.41%
Dec 31, 2024 -42.59%
Sep 30, 2024 -38.35%
Jun 30, 2024 -27.74%
Mar 31, 2024 -12,812.62%
Dec 31, 2023 -2,610.84%
Sep 30, 2023 -51.60%
Jun 30, 2023 -55.56%
Mar 31, 2023 -18,381.88%